Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zanidatamab Zovodotin · ZW49

Bispecific antibody (Biparatopic) · Kills target cells, directed at HER2 (ERBB2) · developed by Zymeworks BC

Phase 1 Most advanced trial (none active)

ZYME Developer

1 Registered trials

What is Zanidatamab Zovodotin?

Zanidatamab zovodotin is a bispecific antibody-drug conjugate targeting two epitopes of HER2 conjugated to a microtubule-disrupting auristatin. Upon binding HER2 on tumor cells and internalization, the cytotoxic payload is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis. It is studied in HER2-expressing cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ZW49
Drug type: Bispecific antibody (Biparatopic)
Targets: HER2 (ERBB2)
Mechanism: Kills target cells, directed at HER2 (ERBB2)
Pathways: microtubule disruption, G2/M phase arrest, apoptosis, HER2 signaling inhibition
Therapy area: Oncology
Developer: Zymeworks BC Inc. (ZYME)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: HKH2GV9PVO

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03821233	Phase 1	HER2-expressing Cancers	Completed	ZYME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HER2-expressing Cancers

Other drugs acting on ERBB2

Neratinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved ADCT-502 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 ELVN-002 Phase 1 Enozertinib Phase 1/2 NVL-330 Phase 1 TTX-MC138 Phase 1/2

More from Zymeworks BC

ZW171 Phase 1 ZW191 Phase 1 ZW251 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ZYME page.

Follow ZYME, the company behind Zanidatamab Zovodotin

See ZYME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZYME catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z